Biological effect of dose distortion by fiducial markers in spot-scanning proton therapy with a limited number of fields: a simulation study.

PURPOSE In accurate proton spot-scanning therapy, continuous target tracking by fluoroscopic x ray during irradiation is beneficial not only for respiratory moving tumors of lung and liver but also for relatively stationary tumors of prostate. Implanted gold markers have been used with great effect for positioning the target volume by a fluoroscopy, especially for the cases of liver and prostate with the targets surrounded by water-equivalent tissues. However, recent studies have revealed that gold markers can cause a significant underdose in proton therapy. This paper focuses on prostate cancer and explores the possibility that multiple-field irradiation improves the underdose effect by markers on tumor-control probability (TCP). METHODS A Monte Carlo simulation was performed to evaluate the dose distortion effect. A spherical gold marker was placed at several characteristic points in a water phantom. The markers were with two different diameters of 2 and 1.5 mm, both visible on fluoroscopy. Three beam arrangements of single-field uniform dose (SFUD) were examined: one lateral field, two opposite lateral fields, and three fields (two opposite lateral fields + anterior field). The relative biological effectiveness (RBE) was set to 1.1 and a dose of 74 Gy (RBE) was delivered to the target of a typical prostate size in 37 fractions. The ratios of TCP to that without the marker (TCP(r)) were compared with the parameters of the marker sizes, number of fields, and marker positions. To take into account the dependence of biological parameters in TCP model, α∕β values of 1.5, 3, and 10 Gy (RBE) were considered. RESULTS It was found that the marker of 1.5 mm diameter does not affect the TCPs with all α∕β values when two or more fields are used. On the other hand, if the marker diameter is 2 mm, more than two irradiation fields are required to suppress the decrease in TCP from TCP(r) by less than 3%. This is especially true when multiple (two or three) markers are used for alignment of a patient. CONCLUSIONS It is recommended that 1.5-mm markers be used to avoid the reduction of TCP as well as to spare the surrounding critical organs, as long as the markers are visible on x-ray fluoroscopy. When 2-mm markers are implanted, more than two fields should be used and the markers should not be placed close to the distal edge of any of the beams.

[1]  Rajat J Kudchadker,et al.  Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer , 2010, Physics in medicine and biology.

[2]  W Schlegel,et al.  An analytical approximation of depth-dose distributions for therapeutic proton beams. , 1996, Physics in medicine and biology.

[3]  Shinichi Shimizu,et al.  Use of implanted markers and interportal adjustment with real-time tracking radiotherapy system to reduce intrafraction prostate motion. , 2011, International journal of radiation oncology, biology, physics.

[4]  Lei Dong,et al.  Reducing metal artifacts in cone-beam CT images by preprocessing projection data. , 2007, International journal of radiation oncology, biology, physics.

[5]  K. Nihei,et al.  Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. , 2011, International journal of radiation oncology, biology, physics.

[6]  R. Mohan,et al.  Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy , 2007, Physics in medicine and biology.

[7]  R. Mohan,et al.  Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate , 2007, Physics in medicine and biology.

[8]  M. V. van Herk,et al.  Physical aspects of a real-time tumor-tracking system for gated radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[9]  D Robertson,et al.  Intensity modulated proton therapy treatment planning using single-field optimization: the impact of monitor unit constraints on plan quality. , 2010, Medical physics.

[10]  Jacob Geleijns,et al.  Metal artifact reduction for CT: development, implementation, and clinical comparison of a generic and a scanner-specific technique. , 2012, Medical physics.

[11]  D J Brenner,et al.  Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.

[12]  B. Bednarz,et al.  Comparison of Particle-Tracking Features in GEANT4 and MCNPX Codes for Applications in Mapping of Proton Range Uncertainty , 2011, Nuclear technology.

[13]  J M Slater,et al.  Conformal proton therapy for early-stage prostate cancer. , 1999, Urology.

[14]  Bernard Gottschalk,et al.  On the scattering power of radiotherapy protons. , 2009, Medical physics.

[15]  Patrick A Kupelian,et al.  Influence of intrafraction motion on margins for prostate radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[16]  C C Ling,et al.  Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data. , 2001, International journal of radiation oncology, biology, physics.

[17]  G. Folger,et al.  The Binary Cascade , 2004 .

[18]  T Bortfeld,et al.  An analytical approximation of the Bragg curve for therapeutic proton beams. , 1997, Medical physics.

[19]  Dong Wook Kim,et al.  Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[20]  X. Allen Li,et al.  HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .

[21]  V. Highland,et al.  Some Practical Remarks on Multiple Scattering , 1975 .

[22]  Zuofeng Li,et al.  Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[23]  O. Jäkel Ranges of ions in metals for use in particle treatment planning , 2006, Physics in Medicine and Biology.

[24]  M Goitein,et al.  Implementation of a model for estimating tumor control probability for an inhomogeneously irradiated tumor. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  S Webb,et al.  A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. , 1993, Physics in medicine and biology.

[26]  T. Sasaki,et al.  Verification of the dose distributions with GEANT4 simulation for proton therapy , 2004, IEEE Symposium Conference Record Nuclear Science 2004..

[27]  M. P. Van Gellekom,et al.  How low is the alpha/beta ratio for prostate cancer? , 2003, International journal of radiation oncology, biology, physics.

[28]  William Y Song,et al.  Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: a radiobiologic analysis. , 2006, International journal of radiation oncology, biology, physics.